The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Improved disease-free survival with blinatumomab plus chemotherapy in pediatric higher-risk B-ALL: AALL1731 study
|
The phase III randomized AALL1731 (NCT03914625) study evaluated the efficacy and safety of two cycles of blinatumomab (15 mg/m2/day for 28 days) plus chemotherapy in children (aged 1 to <10 years) with newly diagnosed SR B-ALL, subcategorized based on risk of relapse to SR-high (n = 301) or SR-average (n = 417). Results were presented at the 66th American Society of Hematology Annual Meeting and Exposition by Rau.1 |
| Key learnings |
| Compared with chemotherapy alone, blinatumomab plus chemotherapy improved the 3-year DFS in both SR-average (HR, 0.33; 90.2% vs 97.5%) and SR-high (HR, 0.45; 84.8% vs 94.1%) pediatric patients with B-ALL. |
| In both SR-average and SR-high groups, the risk of relapse was lower in the blinatumomab plus chemotherapy group compared with the chemotherapy-only group (p = 0.002 for each group). Blinatumomab plus chemotherapy reduced isolated BM relapse, but not isolated CNS relapse (p < 0.001 and p = 0.85, respectively, for the overall cohort). |
| Blinatumomab plus chemotherapy was well tolerated; however, there were higher rates of sepsis and catheter-related infections in patients with SR-average B-ALL. Overall, there was no difference in Grade 4 or 5 infectious toxicity. |
| The findings suggest that the addition of blinatumomab to chemotherapy is a new standard treatment choice for children with newly diagnosed SR B-ALL. |
Abbreviations: B-ALL, B-cell acute lymphoblastic leukemia; BM, bone marrow; CNS, central nervous system; DFS, disease-free survival; HR, hazard ratio; SR, standard risk.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
